Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians
- PMID: 17133612
- PMCID: PMC2063456
- DOI: 10.1002/art.22216
Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians
Abstract
Objective: To define the relative importance (RI) of class II major histocompatibility complex (MHC) alleles and peptide binding motifs as risk or protective factors for juvenile dermatomyositis (DM), and to compare these with HLA associations in adult DM.
Methods: DRB1 and DQA1 typing was performed in 142 Caucasian patients with juvenile DM, and the results were compared with HLA typing data from 193 patients with adult DM and 797 race-matched controls. Random Forests classification and multiple logistic regression were used to assess the RI of the HLA associations.
Results: The HLA-DRB1*0301 allele was a primary risk factor (odds ratio [OR] 3.9), while DQA1*0301 (OR 2.8), DQA1*0501 (OR 2.1), and homozygosity for DQA1*0501 (OR 3.2) were additional risk factors for juvenile DM. These risk factors were not present in patients with adult DM without defined autoantibodies. DQA1 alleles *0201 (OR 0.37), *0101 (OR 0.38), and *0102 (OR 0.51) were identified as novel protective factors for juvenile DM, the latter 2 also being protective factors in adult DM. The peptide binding motif DRB1 (9)EYSTS(13) was a risk factor, and DQA1 motifs F(25), S(26), and (45)(V/A)W(R/K)(47) were protective. Random Forests classification analysis revealed that among the identified risk factors for juvenile DM, DRB1*0301 had a higher RI (100%) than DQA1*0301 (RI 57%), DQA1*0501 (RI 42%), or the peptide binding motifs. In a logistic regression model, DRB1*0301 and DQA1*0201 were the strongest risk and protective factors, respectively, for juvenile DM.
Conclusion: DRB1*0301 is ranked higher in RI than DQA1*0501 as a risk factor for juvenile DM. DQA1*0301 is a newly identified HLA risk factor for juvenile DM, while 3 of the DQA1 alleles studied are newly identified protective factors for juvenile DM.
Similar articles
-
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies.Medicine (Baltimore). 2006 Mar;85(2):111-127. doi: 10.1097/01.md.0000217525.82287.eb. Medicine (Baltimore). 2006. PMID: 16609350
-
Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis.Arthritis Rheum. 1996 Sep;39(9):1507-18. doi: 10.1002/art.1780390910. Arthritis Rheum. 1996. PMID: 8814062
-
Genetic association of HLA-DRB1 multiple polymorphisms with dermatomyositis in Chinese population.HLA. 2017 Dec;90(6):354-359. doi: 10.1111/tan.13171. HLA. 2017. PMID: 29106035
-
Complex interaction between HLA DR and DQ in conferring risk for childhood type 1 diabetes.Eur J Immunogenet. 1999 Oct;26(5):361-72. doi: 10.1046/j.1365-2370.1999.00173.x. Eur J Immunogenet. 1999. PMID: 10553503 Clinical Trial.
-
The heterogeneity of juvenile myositis.Autoimmun Rev. 2007 Mar;6(4):241-7. doi: 10.1016/j.autrev.2006.08.009. Epub 2006 Sep 5. Autoimmun Rev. 2007. PMID: 17317616 Free PMC article. Review.
Cited by
-
Identifying important risk factors for survival in patient with systolic heart failure using random survival forests.Circ Cardiovasc Qual Outcomes. 2011 Jan 1;4(1):39-45. doi: 10.1161/CIRCOUTCOMES.110.939371. Epub 2010 Nov 23. Circ Cardiovasc Qual Outcomes. 2011. PMID: 21098782 Free PMC article.
-
Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis.Arthritis Rheum. 2008 Dec;58(12):3941-50. doi: 10.1002/art.24039. Arthritis Rheum. 2008. PMID: 19035492 Free PMC article.
-
Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis.J Pediatr. 2010 Oct;157(4):653-7. doi: 10.1016/j.jpeds.2010.04.034. J Pediatr. 2010. PMID: 20605164 Free PMC article.
-
Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.Arthritis Rheum. 2009 Jun;60(6):1815-24. doi: 10.1002/art.24555. Arthritis Rheum. 2009. PMID: 19479879 Free PMC article. Clinical Trial.
-
Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment.Paediatr Drugs. 2009;11(6):361-74. doi: 10.2165/11310550-000000000-00000. Paediatr Drugs. 2009. PMID: 19877722 Review.
References
-
- Rider LG, Targoff IN. In: Textbook of the Autoimmune Diseases. Lahita RG, Chiorazzi N, Reeves WH, editors. Philadelphia: Lippincott Williams & Wilkins; 2000. pp. 429–474.
-
- Reed AM, Ytterberg SR. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28:891–916. - PubMed
-
- Shamim EA, Rider LG, Miller FW. Update on the genetics of the idiopathic inflammatory myopathies. Current Opinion in Rheumatology. 2000;12:482–491. - PubMed
-
- Rider LG, Miller FW. Idiopathic inflammatory muscle disease: clinical aspects. Baillieres Best Pract Res Clin Rheumatol. 2000;14(1):37–54. - PubMed
-
- Fall N, Bove KE, Stringer K, Lovell DJ, Brunner HI, Weiss J, et al. Association Between Lack of Angiogenic Responce in Muscle Tissue and High Expression of Angiostatic ELR‐Negative CXC Chemokines in patients With Juvenile Dermatomyositis. Arthritis Rheum. 2005;52:3175–3180. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials